ENDRA Life Sciences Inc. (NDRA) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US29273B5003

Price
4.64 USD
Market cap
6.96 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

ENDRA Life Sciences Inc. financials

Fiscal year2025
Operating income-5.76 m USD
EBIT-7.03 m USD
Net income-7.03 m USD
Diluted EPS – continuing operations-8.93 USD

Full history since 2015, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion analysis. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.